

# Mark D Pegram

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7058084/publications.pdf>

Version: 2024-02-01

79  
papers

21,461  
citations

126907

33  
h-index

71685

76  
g-index

80  
all docs

80  
docs citations

80  
times ranked

17776  
citing authors

#	ARTICLE	IF	CITATIONS
1	Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. <i>New England Journal of Medicine</i> , 2001, 344, 783-792.	27.0	10,216
2	Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2012, 367, 1783-1791.	27.0	3,020
3	Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 5538-5546.	1.6	948
4	Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells. <i>Cancer Research</i> , 2006, 66, 1630-1639.	0.9	846
5	Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 597-609.	27.0	789
6	Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. <i>Oncogene</i> , 1999, 18, 2241-2251.	5.9	645
7	Quantitative Association Between HER-2/neu and Steroid Hormone Receptors in Hormone Receptor-Positive Primary Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2003, 95, 142-153.	6.3	522
8	Rational Combinations of Trastuzumab With Chemotherapeutic Drugs Used in the Treatment of Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2004, 96, 739-749.	6.3	488
9	First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. <i>Journal of Clinical Oncology</i> , 2019, 37, 946-953.	1.6	377
10	Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. <i>Oncogene</i> , 1998, 17, 2235-2249.	5.9	353
11	The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. <i>Oncogene</i> , 1997, 15, 537-547.	5.9	317
12	Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2004, 96, 759-769.	6.3	271
13	Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 573.	7.1	217
14	Augmented HER-2-Specific Immunity during Treatment with Trastuzumab and Chemotherapy. <i>Clinical Cancer Research</i> , 2007, 13, 5133-5143.	7.0	194
15	Neratinib Efficacy and Circulating Tumor DNA Detection of <i>HER2</i> Mutations in <i>HER2</i> Nonamplified Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5687-5695.	7.0	170
16	Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 3755-3763.	7.0	167
17	Mitochondrial copper depletion suppresses triple-negative breast cancer in mice. <i>Nature Biotechnology</i> , 2021, 39, 357-367.	17.5	163
18	Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells. <i>Oncogene</i> , 1999, 18, 6050-6062.	5.9	131

#	ARTICLE	IF	CITATIONS
19	Phase I Dose Escalation and Pharmacokinetic Study of Lapatinib in Combination With Trastuzumab in Patients With Advanced ErbB2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 3317-3323.	1.6	118
20	Anti-HER2 scFv-Directed Extracellular Vesicle-Mediated mRNA-Based Gene Delivery Inhibits Growth of HER2-Positive Human Breast Tumor Xenografts by Prodrug Activation. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1133-1142.	4.1	107
21	Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/ protein and vascular endothelial growth factor. <i>Seminars in Oncology</i> , 2002, 29, 29-37.	2.2	73
22	SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx).. <i>Journal of Clinical Oncology</i> , 2019, 37, 1000-1000.	1.6	71
23	Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	67
24	Application and potential limitations of animal models utilized in the development of trastuzumab (Herceptin®): A case study. <i>Advanced Drug Delivery Reviews</i> , 2006, 58, 723-734.	13.7	62
25	Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 2667-2675.	1.6	58
26	Hydrogel Pore Size Modulation for Enhanced Single Cell Western Blotting. <i>Advanced Materials</i> , 2016, 28, 327-334.	21.0	57
27	Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer. <i>Tumor Biology</i> , 2016, 37, 9825-9835.	1.8	52
28	Whole genome in vivo RNAi screening identifies the leukemia inhibitory factor receptor as a novel breast tumor suppressor. <i>Breast Cancer Research and Treatment</i> , 2012, 135, 79-91.	2.5	51
29	Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain. <i>Cancer Research</i> , 2016, 76, 3702-3710.	0.9	51
30	Role of Fcγ3 receptors in HER2-targeted breast cancer therapy. , 2022, 10, e003171.		47
31	Association Studies of Fcγ3 Receptor Polymorphisms with Outcome in HER2+ Breast Cancer Patients Treated with Trastuzumab in NCCTG (Alliance) Trial N9831. <i>Cancer Immunology Research</i> , 2014, 2, 962-969.	3.4	44
32	PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study. <i>British Journal of Cancer</i> , 2019, 120, 172-182.	6.4	43
33	Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2 positive breast cancer. <i>European Journal of Cancer</i> , 2019, 120, 1-9.	2.8	39
34	First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1442-1453.	4.1	38
35	PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2012, 136, 683-692.	2.5	36
36	HER2-Overexpressing/Amplified Breast Cancer as a Testing Ground for Antibody-Drug Conjugate Drug Development in Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 775-786.	7.0	36

#	ARTICLE	IF	CITATIONS
37	Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer. <i>Breast Cancer Research</i> , 2016, 18, 34.	5.0	34
38	Extracellular Vesicle-Mediated <i>In Vitro</i> Transcribed mRNA Delivery for Treatment of HER2+ Breast Cancer Xenografts in Mice by Prodrug CB1954 without General Toxicity. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 858-867.	4.1	33
39	Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples. <i>Breast Cancer Research and Treatment</i> , 2001, 67, 223-233.	2.5	31
40	The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1258-1267.	7.0	31
41	Rapid Reduction in Breast Cancer Mortality With Inorganic Arsenic in Drinking Water. <i>EBioMedicine</i> , 2014, 1, 58-63.	6.1	28
42	Targeted prodrug treatment of HER-2-positive breast tumor cells using trastuzumab and paclitaxel linked by A-Z-CINNTM Linker. <i>Journal of Experimental Therapeutics and Oncology</i> , 2003, 3, 27-35.	0.5	26
43	A careful reassessment of anthracycline use in curable breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 134.	5.2	25
44	Abstract LB-63: Relationship between tumor biomarkers (BM) and efficacy in EMILIA, a phase III study of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC).. <i>Cancer Research</i> , 2013, 73, LB-63-LB-63.	0.9	23
45	Can We Circumvent Resistance To ErbB2-Targeted Agents By Targeting Novel Pathways?. <i>Clinical Breast Cancer</i> , 2008, 8, S121-S130.	2.4	22
46	Niclosamide inhibits epithelial-mesenchymal transition and tumor growth in lapatinib-resistant human epidermal growth factor receptor 2-positive breast cancer. <i>International Journal of Biochemistry and Cell Biology</i> , 2016, 71, 12-23.	2.8	22
47	HER-2/neu overexpression and <i>in vitro</i> chemosensitivity to CMF and FEC in primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2001, 69, 53-63.	2.5	21
48	Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars. <i>Journal of Clinical Oncology</i> , 2020, 38, 1070-1080.	1.6	19
49	RNA Based Approaches to Profile Oncogenic Pathways From Low Quantity Samples to Drive Precision Oncology Strategies. <i>Frontiers in Genetics</i> , 2020, 11, 598118.	2.3	18
50	Advances in Therapeutic Approaches for Triple-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2021, 21, 383-390.	2.4	18
51	Treating the HER2 Pathway in Early and Advanced Breast Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 751-765.	2.2	15
52	A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, e251-e260.	2.4	15
53	Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG). <i>Clinical Breast Cancer</i> , 2020, 20, 183-193.	2.4	13
54	Phase II trial of neratinib for HER2 mutated, non-amplified metastatic breast cancer (HER2 <sup>mut</sup> MBC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 516-516.	1.6	13

#	ARTICLE	IF	CITATIONS
55	A first-in-class, first-in-human phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of Hu5F9-G4, an anti-CD47 monoclonal antibody (mAb), in patients with advanced solid tumors.. Journal of Clinical Oncology, 2018, 36, 3002-3002.	1.6	13
56	Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG). Breast Cancer Research and Treatment, 2018, 169, 1-7.	2.5	12
57	Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer. Breast Cancer Research, 2018, 20, 52.	5.0	12
58	Docetaxel and Herceptin: Foundation for Future Strategies. Oncologist, 2001, 6, 22-25.	3.7	11
59	Electrophoretic cytopathology resolves ERBB2 forms with single-cell resolution. Npj Precision Oncology, 2018, 2, 10.	5.4	11
60	Innovative Strategies: Targeting Subtypes in Metastatic Breast Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 65-77.	3.8	11
61	A Novel HER2-targeted Antibody-Drug Conjugate Offers the Possibility of Clinical Dosing at Trastuzumab-equivalent Exposure Levels. Molecular Cancer Therapeutics, 2020, 19, 1866-1874.	4.1	11
62	Research advances and new challenges in overcoming triple-negative breast cancer. , 2021, 4, 517-542.		11
63	Induced pluripotent stem cells as a novel cancer vaccine. Expert Opinion on Biological Therapy, 2019, 19, 1191-1197.	3.1	10
64	Real-world Evidence of Diagnostic Testing and Treatment Patterns in US Patients With Breast Cancer With Implications for Treatment Biomarkers From RNA Sequencing Data. Clinical Breast Cancer, 2021, 21, e340-e361.	2.4	10
65	Docetaxel and Herceptin: Foundation for Future Strategies. Oncologist, 2001, 6, 22-25.	3.7	10
66	Neratinib in ERBB2-Positive Brain Metastases. JAMA Oncology, 2016, 2, 1541.	7.1	8
67	Possible available treatment option for early stage, small, node-negative, and HER2-overexpressing breast cancer. Breast Cancer, 2012, 19, 95-103.	2.9	5
68	Single-cell immunoblotting resolves estrogen receptor- $\alpha$ isoforms in breast cancer. PLoS ONE, 2021, 16, e0254783.	2.5	5
69	Biosimilars in an era of rising oncology treatment options. Future Oncology, 2021, 17, 3881-3892.	2.4	5
70	Four-year follow-up of a phase III study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2-positive early or locally advanced breast cancer in neoadjuvant setting.. Journal of Clinical Oncology, 2020, 38, 578-578.	1.6	5
71	SOPHIA: A phase 3, randomized study of margetuximab (M) plus chemotherapy (CTX) vs trastuzumab (T) plus CTX in the treatment of patients with HER2+ metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2016, 34, TPS630-TPS630.	1.6	4
72	Abstract PD8-01: Phase 3 SOPHIA study of margetuximab (M) + chemotherapy (CTX) vs trastuzumab (T) + CTX in patients (pts) with HER2+ metastatic breast cancer (MBC) after prior anti-HER2 therapies: Final overall survival (OS) analysis. Cancer Research, 2022, 82, PD8-01-PD8-01.	0.9	4

#	ARTICLE	IF	CITATIONS
73	Evaluation of survival by ADCC status: Subgroup analysis of SB3 (Trastuzumab Biosimilar) and reference trastuzumab in patients with HER2-positive early breast cancer at three-year follow-up.. Journal of Clinical Oncology, 2019, 37, 580-580.	1.6	3
74	•Inhibition of HER2 Yields Horizontal Gains in the Clinic. Clinical Cancer Research, 2015, 21, 2663-2665.	7.0	2
75	SOPHIA analysis by chemotherapy (Ctx) choice: A phase III (P3) study of margetuximab (M) + Ctx versus trastuzumab (T) + Ctx in patients (pts) with pretreated HER2+ metastatic (met) breast cancer (MBC).. Journal of Clinical Oncology, 2020, 38, 1040-1040.	1.6	2
76	A Phase 1 study to evaluate the safety, pharmacokinetics, immunogenicity, and antitumor activity of MEDI4276 in patients with select HER2-expressing advanced solid tumors.. Journal of Clinical Oncology, 2016, 34, TPS632-TPS632.	1.6	2
77	A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs. placebo in combination with capecitabine (C) and trastuzumab (Tz) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (mBC) (HER2CLIMB).. Journal of Clinical Oncology, 2017, 35, TPS1107-TPS1107.	1.6	1
78	Reply to J. Wei et al. Journal of Clinical Oncology, 2021, , JCO2101973.	1.6	1
79	Quantitative measurement of total erbB2 (H2T), p110 t-erbB2, and erbB2:erbB3 (H23D) heterodimer expression and p110 t-erbB2 in malignant progression from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC).. Journal of Clinical Oncology, 2018, 36, 12089-12089.	1.6	0